This is the authors' abstract. We don't add key points for this paper.
AOMs have established efficacy and effectiveness for weight loss even beyond 52 weeks. Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice for combating obesity and its metabolic consequences such as metabolic dysfunction-associated steatotic liver disease.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lupianez‐Merly et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: